Recent News

Novel Approach to Noninvasive Identification of CD117-Positive Kidney Tumors

Novel Blood Test Used to Predict Kidney Cancer Risk and Survival

Single-Cell Transcriptomes Reveal Cellular Identity of Renal Carcinomas

Renal Function After Partial Nephrectomy: To Clamp or Not to Clamp

FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab in Urothelial Cancer

FDA Grants Fast Track Designation to VB4-845 for Treatment of Type of Bladder Cancer

For Early Kidney Cancer, Which Surgical Approach to Partial Nephrectomy Is Best?

Immunosuppressants and Squamous Cell Carcinoma in Renal Transplant Recipients

Does Renal Transplant Rejection Influence Risk of Developing Squamous Cell Carcinoma?

Potential Therapeutic Target Identified in Clear Cell Renal Cell Carcinoma

Delayed Skin Reactions Reported With PD-1 Inhibitors

Percutaneous Ablation as Nonsurgical Alternative for Patients With T1a Kidney Cancer

Does Prior Antibiotic Use Affect Treatment Outcomes in Renal Cell Carcinoma?

Use of Pembrolizumab Before Radical Cystectomy in Urothelial Bladder Cancer

Early Study of Antibody-Drug Conjugate in Urothelial Cancer

Improved Quality of Life With Combination Immunotherapy in Advanced Kidney Cancer

ASCO 2018: Phase II Study Results With Erdafitinib in Metastatic Urothelial Cancer

FDA Restricts Use of Pembrolizumab or Atezolizumab in Some Patients Treated for Urothelial Carcinoma

Does Statin and Sartan Use Affect Outcomes in Patients Treated for Kidney Cancer?

ASCO 2018: ABACUS Investigates Atezolizumab Before Nephrectomy in Bladder Cancer

ASCO 2018: First-Line Pembrolizumab Monotherapy in Advanced Renal Cell Carcinoma

ASCO 2018: Is Adjuvant Therapy of Benefit in Children With Resected Kidney Cancer?

ASCO 2018: Can Some Patients With Metastatic Kidney Cancer Avoid Surgery With Sunitinib Alone?

AUA 2018: Risk Factors for pN1 Status in Surgically Treated Patients With Kidney Cancer

Predicting Outcomes in Renal Carcinoma Using EMT and Immune Signatures

FDA Alert: Efficacy Issues Identified in Trials of Pembrolizumab or Atezolizumab in Urothelial Cancer

AUA 2018: Effect of Cytoreductive Nephrectomy on Survival in Metastatic Non–Clear Cell Kidney Cancer

AUA 2018: Should Guidelines for Renal Cell Carcinoma Surveillance Be Revised?

Combination of Avelumab and Axitinib in First-Line Treatment of Clear Cell Kidney Cancer

Tivozanib After Sorafenib in Patients With Renal Cell Carcinoma

Simultaneous Administration of Chemotherapy and Checkpoint Inhibition in Metastatic Urothelial Cancer

FDA Grants Fast Track Designation to CB-839 in Combination With Cabozantinib for Advanced RCC

NCCN Annual Conference 2018: Debut of New Guidelines on Immunotherapy-Related Toxicity

FDA Approves Nivolumab/Ipilimumab Combination in Intermediate- or Poor-Risk RCC

Predicting Survival in Patients With Kidney Cancer: Do Sex Differences in Visceral Fat Matter?

FDA Grants Fast Track Designation to TAR-200 for the Treatment of Bladder Cancer

FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin for Advanced or Metastatic Urothelial Cancer